NASDAQ:BGNE - Beigene Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $158.56 +0.88 (+0.56 %) (As of 08/16/2018 09:40 AM ET)Previous Close$157.68Today's Range$157.38 - $160.7552-Week Range$65.58 - $220.10Volume15,034 shsAverage Volume358,914 shsMarket Capitalization$8.89 billionP/E Ratio-71.10Dividend YieldN/ABeta0.78 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of targeted therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317; and with Merck KGaA to research and develop on BGB-290 and BGB-283. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands. Receive BGNE News and Ratings via Email Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:BGNE CUSIPN/A Webwww.beigene.com Phone34-59-494-12 Debt Debt-to-Equity Ratio0.16 Current Ratio8.14 Quick Ratio8.10 Price-To-Earnings Trailing P/E Ratio-71.10 Forward P/E Ratio-17.44 P/E GrowthN/A Sales & Book Value Annual Sales$238.39 million Price / Sales35.76 Cash FlowN/A Price / CashN/A Book Value$15.02 per share Price / Book10.56 Profitability EPS (Most Recent Fiscal Year)($2.23) Net Income$-93,100,000.00 Net Margins-75.19% Return on Equity-24.14% Return on Assets-17.84% Miscellaneous Employees900 Outstanding Shares53,760,000Market Cap$8.89 billion Beigene (NASDAQ:BGNE) Frequently Asked Questions What is Beigene's stock symbol? Beigene trades on the NASDAQ under the ticker symbol "BGNE." How were Beigene's earnings last quarter? Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($2.92) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.12) by $0.80. The business earned $52.80 million during the quarter, compared to analyst estimates of $22.53 million. Beigene had a negative net margin of 75.19% and a negative return on equity of 24.14%. The business's revenue for the quarter was up 5279999900.0% compared to the same quarter last year. During the same period last year, the company earned ($1.52) earnings per share. View Beigene's Earnings History. When is Beigene's next earnings date? Beigene is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Beigene. What price target have analysts set for BGNE? 7 brokers have issued 1 year target prices for Beigene's shares. Their forecasts range from $138.00 to $225.00. On average, they anticipate Beigene's share price to reach $187.00 in the next year. This suggests a possible upside of 17.9% from the stock's current price. View Analyst Price Targets for Beigene. What is the consensus analysts' recommendation for Beigene? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene. What are Wall Street analysts saying about Beigene stock? Here are some recent quotes from research analysts about Beigene stock: 1. Maxim Group analysts commented, "BeiGene reported additional data for tislelizumab (PD-1) in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) from its China-based study, demonstrating continued durable responses." (7/30/2018) 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (7/10/2018) Who are some of Beigene's key competitors? Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY). Who are Beigene's key executives? Beigene's management team includes the folowing people: Mr. John V. Oyler, Founder, Chairman and Chief Exec. Officer (Age 50)Dr. Heng Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 55)Dr. Amy C. Peterson M.D., Chief Medical Officer of Immuno-Oncology (Age 51)Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 45)Dr. Xiaobin Wu, Pres & Gen. Mang. of China When did Beigene IPO? (BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager. Has Beigene been receiving favorable news coverage? News articles about BGNE stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Beigene earned a media and rumor sentiment score of 0.19 on Accern's scale. They also assigned media headlines about the company an impact score of 46.25 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Beigene. Who are Beigene's major shareholders? Beigene's stock is owned by many different of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (22.25%), FMR LLC (10.00%), Morgan Stanley (0.93%), OppenheimerFunds Inc. (0.91%), BlackRock Inc. (0.81%) and Janus Henderson Group PLC (0.72%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for Beigene. Which institutional investors are selling Beigene stock? BGNE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Indus Capital Partners LLC, KEYWISE CAPITAL MANAGEMENT Ltd, Bank of America Corp DE, Orbimed Advisors LLC, OppenheimerFunds Inc., Bellevue Group AG and Greenwoods Asset Management Ltd. Company insiders that have sold Beigene company stock in the last year include Amy C Peterson, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Insider Buying and Selling for Beigene. Which institutional investors are buying Beigene stock? BGNE stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Renaissance Technologies LLC, Victory Capital Management Inc., Morgan Stanley, Millennium Management LLC, Harvest Fund Management Co. Ltd, BlackRock Inc. and Barings LLC. Company insiders that have bought Beigene stock in the last two years include Bros Advisors Lp Baker and Thomas Malley. View Insider Buying and Selling for Beigene. How do I buy shares of Beigene? Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Beigene's stock price today? One share of BGNE stock can currently be purchased for approximately $158.56. How big of a company is Beigene? Beigene has a market capitalization of $8.89 billion and generates $238.39 million in revenue each year. The company earns $-93,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Beigene employs 900 workers across the globe. How can I contact Beigene? Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected] MarketBeat Community Rating for Beigene (NASDAQ BGNE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 276 (Vote Outperform)Underperform Votes: 225 (Vote Underperform)Total Votes: 501MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/16/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?